TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00736515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide MR and Insulin Glargine Injection
Description: Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biosynthetic Human Insulin Injection
Description: Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
Study: NCT01797770

Intervention type: DRUG
Intervention: polyethylene glycol
Description: mechanical bowel preparation with polyethylene glycol one day prior to surgery

Intervention type: OTHER
Intervention: No Preparation
Description: No laxatives or bowel preparation
Study: NCT02013583

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational registry. No interventions are required or provided.
Study: NCT01325792

Intervention type: DEVICE
Intervention: GORE® BIO-A® Tissue Reinforcement
Description: Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
Study: NCT02336126

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biopsychological intervention
Study: NCT01661582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT/PET Myocardial Perfusion Imaging using O-15 water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CT/PET Myocardial Perfusion Imaging using O-15 water

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coronary blood flow measured by doppler echocardiography

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coronary blood flow measured by doppler echocardiography
Study: NCT03174002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Study: NCT04083729

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mitral Commissurotomy
Description: Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Mitral Commissurotomy
Description: Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon or multitrack technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area \> 1.5 square cm with less than moderate to severe mitral regurgitation.
Study: NCT01456767

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10\^11 life bacteria are consumed by each participant.~Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells.
Study: NCT01204723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Aprepitant
Description: Placebo Aprepitant 0 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Aprepitant
Description: Placebo Aprepitant 0 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Aprepitant
Description: Placebo Aprepitant 0 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Aprepitant
Description: Active Aprepitant 160 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Aprepitant
Description: Active Aprepitant 160 mg once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Aprepitant
Description: Active Aprepitant 160 mg once daily for 5 days
Study: NCT00522132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: intravenous application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: intravenous application
Study: NCT03900689

Intervention type: OTHER
Intervention: Part 1 Survey Group
Description: At the first study visit, participants will answer a series of survey questions about their neighborhoods, educational levels, social activities, access to transportation and food, healthcare management and where participants find social and spiritual support. General information such as age, ethnicity and address will also be collected.

Intervention type: OTHER
Intervention: Part 2 Focus Group
Description: If participants from Part 1 agree to be contacted for Part 2, participants will be included in a focus group to explore unexpected findings and further investigate social determinants identified in Part 1.
Study: NCT00527891

Intervention type: PROCEDURE
Intervention: Signa Excite 3.0 T MRI Scan
Description: Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
Study: NCT02236351

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pinch Patch/ flat Patch

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pinch Patch/ flat Patch
Study: NCT03841084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Conservative oxygen management strategy- reduces oxygen on the inoblender in the ECMO circuit.~Liberal oxygen management strategy - does not reduce the oxygen on the inoblender via the ECMO circuit
Study: NCT04185597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFP Intervention: Delivered by Community Farmers
Description: Homestead food production (HFP) supported by community farmers, Social and Behavior Change Communication (SBCC), strengthened health services, and referrals to health and other services

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFP Intervention: Delivered by agricultural Retailers
Description: HFP supported by retailers, SBCC, strengthened health services, and referrals to health and other services

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Current Standard of Practice
Study: NCT03279393

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluorodeoxyglucose (FDG)-PET/MRI
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorodeoxyglucose (FDG)-PET/MRI
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorodeoxyglucose (FDG)-PET/MRI
Description: Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
Study: NCT02639351

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 50 ug of LHD153R
Description: IM vaccination of 1 dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MenC-CRM adjuavnted with 100 ug of LHD153R
Description: IM vaccination of 1 dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C-CRM Conjugate Vaccine (MenC-CRM)
Description: IM vaccination of 1 dose of 0.5 mL
Study: NCT00601952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Description: The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control Condition (ACC)
Description: The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
Study: NCT04906863

Intervention type: OTHER
Intervention: Neurocognitive testing
Description: Brief memory test

Intervention type: OTHER
Intervention: Neurocognitive testing
Description: Brief memory test
Study: NCT03018548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
Study: NCT03690154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FN-1501
Description: Eligible patients will receive a single intravenous infusion of study drug on Days 1, 3, 5, 8, 10, and 12 of a 21-day cycle. Dosing will begin at 2.5 mg once per day on the assigned days. Dose escalation will use the traditional 3+3 design and follow a modified Fibonacci sequence until MTD is reached. Increments of 33% in the dose of FN-1501 will be undertaken after reaching 30 mg/day. At least 3 patients will be enrolled in each cohort. Administration of FN-1501 will be continued until disease progression, intolerable toxicity, withdrawal of consent, or termination according to the Principal Investigator's judgment or at the sponsor's request.
Study: NCT00619008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum low carbohydrate diet
Description: 6 week ad libitum low carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum High Complex Carbohydrate Diet
Description: 6 week ad libitum high complex carbohydrate diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-restricted high complex carbohydrate diet
Description: 6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
Study: NCT03705481

Intervention type: DEVICE
Group type: OTHER
Intervention: Remote treatment of PCI.
Description: To evaluate the safety and performance of CorPath GRX POP System, in the ReMOTE (location outside hospital) delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures.
Study: NCT01727960

Intervention type: BEHAVIORAL
Intervention: Education and posture correction
Description: a lecture concerning the fine posture for health and exercises
Study: NCT00348140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 2mg
Description: Rosiglitazone Extended Release 2mg OD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone Extended Release 8mg
Description: Rosiglitazone Extended Release 8mg OD

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00516919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenical + behavioral intervention
Description: 120 mg TID; Behavioral weight loss in Spanish

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention + placebo
Description: Behavioral weight loss treatment in Spanish Placebo TID
Study: NCT01872455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 rich diet
Description: This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual diet
Description: Usual diet of the patients
Study: NCT04686422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetric PowerFill
Description: Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the PowerCure system.
Study: NCT00844493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: 7 or 8 logs of the bacteria with bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: Bacteria in a dose of 8 logs with CeraVacx buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli strain H10407 and buffer
Description: Bacteria in a dose of 7 logs and CeraVacx buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E coli H10407 and buffer
Description: Bacteria in a dose of 8 logs with bicarbonate buffer
Study: NCT01997151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Pregnancy: Step by Step
Study: NCT01804231

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-FCH PET/MRI imaging
Description: Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
Study: NCT04906863

Intervention type: OTHER
Intervention: Medical questionnaire
Description: Collection of medical history

Intervention type: OTHER
Intervention: Medical questionnaire
Description: Collection of medical history
Study: NCT01508455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study: NCT04095455

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectoral nerves block group
Description: ultrasound guided block of nerve supply of surgical site

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus magnesium group
Description: Patients received 40 mg/kg of magnesium sulphate infusion in 100cc normal saline, as a bolus dose, in addition to 0.2mg/kg of ketamine as a bolus dose, 15 min before the induction of general anesthesia. This was followed by intraoperative continuous infusion of 10 mg/kg/h of magnesium sulphate combined with infusion of 0.1mg/kg/h ketamine that was started before skin incision and continued until completion of skin closure via infusion pump (Atom Syringe Pump S-1235).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Normal saline infusion with similar rate and volume to KM infusion was used as a placebo.
Study: NCT04052841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal pulsation
Description: Participants underwent a single LipiFlow® thermal pulsation system (TearScience Inc., Morrisville, NC,USA) treatment on the first visit: after lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) and instillation of anesthetic eye drops (Alcaine, proparacaine hydrochloride 0.4 ml/2mg) in both eyes, sterile eye cups were placed on to the conjunctival sac as instructed by the manufacturer, after 12 minutes of upper and lower palpebral conjunctival surfaces heat while simultaneously graded pulsatile pressure applying, eye cups were removed slightly.
Study: NCT04906863

Intervention type: OTHER
Intervention: Medical questionnaire
Description: Collection of medical history
Study: NCT04052841

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light therapy
Description: Lid hygiene with wet cotton swabs(OCuSOFT, Inc., Texas, USA) before treatment. Intense pulsed light (IPL) with a range of wavelength (570 or 620 nm) was performed every 3 weeks，3 times in total (0, 3w, 6w). 10 pulses were transmited from one tragus through nose to the other tragus was a single pass, each treatment needed to do 2 passes. Manual lid massage was done after per IPL treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual warm compresses
Description: Lids hygiene of both eyes with wet cotton swabs(OCuSOFT, Inc., Texas, USA).Commercial heated eye patch was use for 10 min. Manual lid massage every 2 weeks, 5 times in total(0，2w, 4w, 4w, 8w).
Study: NCT01656525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 75 mg subcutaneous doses every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 105 mg subcutaneous doses every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: 225 mg subcutaneous doses every 4 weeks for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous doses every 4 weeks for 24 weeks
Study: NCT03068715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TBS-DLPFC
Description: Participants in the active stimulation group will receive intermittent TBS to left DLPFC. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 90% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TBS-DLPFC
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open label TBS-DLPFC
Description: All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Open label TBS-DLPFC
Description: All patients will have the option to receive active, open label aTBS treatment after the 1-month mark, following the blinded phase.~Stimulation will be delivered to the L-DLPFC using a MagPro stimulator or Nexstim TMS device.
Study: NCT04427254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
Description: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies
Study: NCT02598830

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 dissolved in olive oil, encapsuled

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil, encapsuled